Physician profile
Patty Fleming
NPI 1679095798
$5,272.40
in general payments reported to CMS, 2019-2025
44 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $885 · 2023: $1,257 · 2024: $1,545 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,815.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,182.83 | 2021-2025 | |
| Lundbeck LLC | $358.80 | 2022-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $262.65 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $239.35 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $195.92 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $165.43 | 2022 | |
| Glaxosmithkline, LLC. | $138.22 | 2021-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Novartis Pharmaceuticals Corporation | $124.14 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $118.27 | 2021-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $114.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.49 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $92.61 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.50 | 2021-2024 | Trintellix |
| Amgen INC. | $82.08 | 2023-2025 | Repatha, Otezla, Prolia |
| Xeris Pharmaceuticals, INC. | $82.03 | 2023-2024 | Gvoke Hypopen |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patty Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.